NO321571B1 - Fremgangsmate for immunologisk pavisning av prionsykdom, diagnostisk testsett til slik pavisning, samt anvendelse av testsettet. - Google Patents
Fremgangsmate for immunologisk pavisning av prionsykdom, diagnostisk testsett til slik pavisning, samt anvendelse av testsettet. Download PDFInfo
- Publication number
- NO321571B1 NO321571B1 NO19984602A NO984602A NO321571B1 NO 321571 B1 NO321571 B1 NO 321571B1 NO 19984602 A NO19984602 A NO 19984602A NO 984602 A NO984602 A NO 984602A NO 321571 B1 NO321571 B1 NO 321571B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- amino acid
- acid positions
- prp
- correspond
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 63
- 208000024777 Prion disease Diseases 0.000 title claims description 18
- 238000002405 diagnostic procedure Methods 0.000 title claims description 11
- 238000012360 testing method Methods 0.000 title claims description 10
- 230000001900 immune effect Effects 0.000 title claims description 7
- 238000012216 screening Methods 0.000 title 2
- 208000008864 scrapie Diseases 0.000 claims description 58
- 241001494479 Pecora Species 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 241001465754 Metazoa Species 0.000 claims description 27
- 238000003745 diagnosis Methods 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 230000001594 aberrant effect Effects 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 9
- 108010067770 Endopeptidase K Proteins 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 206010023497 kuru Diseases 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 241000699800 Cricetinae Species 0.000 claims 2
- 241000282575 Gorilla Species 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 101150051135 Mink1 gene Proteins 0.000 claims 2
- 108090000143 Mouse Proteins Proteins 0.000 claims 2
- 108090000244 Rat Proteins Proteins 0.000 claims 2
- 108091000054 Prion Proteins 0.000 description 90
- 102000029797 Prion Human genes 0.000 description 90
- 235000018102 proteins Nutrition 0.000 description 22
- 210000001165 lymph node Anatomy 0.000 description 21
- 210000002741 palatine tonsil Anatomy 0.000 description 20
- 210000003563 lymphoid tissue Anatomy 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 11
- 230000002788 anti-peptide Effects 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 210000005004 lymphoid follicle Anatomy 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 101001056878 Homo sapiens Squalene monooxygenase Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000012631 diagnostic technique Methods 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 210000004201 immune sera Anatomy 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108700021402 PrP 27-30 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 101001095054 Ovis aries Major prion protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010007288 PrPSc Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200917 | 1996-04-03 | ||
| PCT/NL1997/000166 WO1997037227A1 (fr) | 1996-04-03 | 1997-04-02 | Procede de detection de maladies a prions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984602D0 NO984602D0 (no) | 1998-10-01 |
| NO984602L NO984602L (no) | 1998-12-03 |
| NO321571B1 true NO321571B1 (no) | 2006-06-06 |
Family
ID=8223847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984602A NO321571B1 (no) | 1996-04-03 | 1998-10-01 | Fremgangsmate for immunologisk pavisning av prionsykdom, diagnostisk testsett til slik pavisning, samt anvendelse av testsettet. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6972177B1 (fr) |
| EP (1) | EP0891552B2 (fr) |
| JP (1) | JP3333213B2 (fr) |
| AR (1) | AR006494A1 (fr) |
| AT (1) | ATE236407T1 (fr) |
| AU (1) | AU713529B2 (fr) |
| BR (1) | BR9708421A (fr) |
| CA (1) | CA2250800C (fr) |
| DE (1) | DE69720433T3 (fr) |
| DK (1) | DK0891552T4 (fr) |
| NO (1) | NO321571B1 (fr) |
| NZ (1) | NZ332132A (fr) |
| WO (1) | WO1997037227A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2319607A (en) * | 1996-11-23 | 1998-05-27 | Electrophoretics International | Detection of prion proteins in mononuclear cells |
| ES2209108T3 (es) * | 1997-02-06 | 2004-06-16 | Enfer Technology Limited | Ensayo inmunologico para encefalopatias espongiformes. |
| US6165784A (en) * | 1997-10-14 | 2000-12-26 | The United States Of America As Represented By The Secretary Of Agriculture | Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies |
| DE19804216C2 (de) * | 1998-02-03 | 1999-12-16 | Schebo Tech Gmbh | Verfahren zum Nachweis von zentralnervösem Gewebe in Erzeugnissen, insbesondere in Fleischerzeugnissen, sowie ein Testkit hierzu |
| AU2580900A (en) | 1999-02-11 | 2000-08-29 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Prion test |
| US6605445B1 (en) | 1999-02-22 | 2003-08-12 | Bayer Corporation | Rapid method of determining clearance of prion protein |
| DE19918141A1 (de) * | 1999-04-21 | 2000-10-26 | Boehringer Ingelheim Vetmed | Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien |
| WO2001019867A1 (fr) * | 1999-09-14 | 2001-03-22 | Memorec Stoffel Gmbh | Proteine apparentee au prion |
| FR2806802B1 (fr) * | 2000-03-24 | 2002-06-21 | Eurofins Scient | Procede et installation pour confirmer l'absence dans la viande de proteines prion infectieuses |
| DE10108099A1 (de) * | 2001-02-19 | 2002-09-12 | Cenas Ag | Verfahren zum Nachweis spezifischer Proteine und Verwendung |
| EP1382971A1 (fr) * | 2002-07-17 | 2004-01-21 | Pepscan Systems B.V. | Detection de maladie a prion |
| US20060184001A1 (en) * | 2005-02-02 | 2006-08-17 | Minkoff Lawrence A | Method for MRI scanning of animals for transmissible spongiform encephalopathies |
| US7834144B2 (en) | 2005-09-09 | 2010-11-16 | Novartis Ag | Prion-specific peptoid reagents |
| US20120107321A1 (en) * | 2009-03-02 | 2012-05-03 | The University Of British Columbia | Antibodies And Epitopes Specific To Misfolded Prion Protein |
| JP5861256B2 (ja) * | 2011-01-25 | 2016-02-16 | 富士通株式会社 | 農作業支援方法及び農作業支援装置 |
| US20220313802A1 (en) * | 2019-05-10 | 2022-10-06 | New York University | Compositions and methods for the treatment and prevention of prion disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806627A (en) | 1987-05-29 | 1989-02-21 | Research Foundation Of Mental Hygiene Inc. | Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins |
| WO1993023432A1 (fr) * | 1992-05-15 | 1993-11-25 | New York University | Polypeptides de pion solubles et procedes de detection et de purification |
| AU707484B2 (en) * | 1995-09-14 | 1999-07-08 | Regents Of The University Of California, The | Antibodies specific for native PrPsc |
| US6165784A (en) | 1997-10-14 | 2000-12-26 | The United States Of America As Represented By The Secretary Of Agriculture | Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies |
| US6150172A (en) | 1999-01-08 | 2000-11-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method and kit for extracting prion protein |
-
1997
- 1997-04-02 US US09/155,794 patent/US6972177B1/en not_active Expired - Fee Related
- 1997-04-02 AT AT97914658T patent/ATE236407T1/de not_active IP Right Cessation
- 1997-04-02 AU AU21808/97A patent/AU713529B2/en not_active Ceased
- 1997-04-02 EP EP97914658A patent/EP0891552B2/fr not_active Expired - Lifetime
- 1997-04-02 JP JP53515797A patent/JP3333213B2/ja not_active Ceased
- 1997-04-02 CA CA002250800A patent/CA2250800C/fr not_active Expired - Fee Related
- 1997-04-02 BR BR9708421A patent/BR9708421A/pt not_active Application Discontinuation
- 1997-04-02 DE DE69720433T patent/DE69720433T3/de not_active Expired - Lifetime
- 1997-04-02 WO PCT/NL1997/000166 patent/WO1997037227A1/fr active IP Right Grant
- 1997-04-02 NZ NZ332132A patent/NZ332132A/en not_active IP Right Cessation
- 1997-04-02 DK DK97914658T patent/DK0891552T4/da active
- 1997-04-03 AR ARP970101332A patent/AR006494A1/es active IP Right Grant
-
1998
- 1998-10-01 NO NO19984602A patent/NO321571B1/no not_active IP Right Cessation
-
2004
- 2004-09-24 US US10/949,880 patent/US7211401B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2250800A1 (fr) | 1997-10-09 |
| AU713529B2 (en) | 1999-12-02 |
| DK0891552T3 (da) | 2003-07-21 |
| US7211401B2 (en) | 2007-05-01 |
| NZ332132A (en) | 2000-02-28 |
| JP2000505559A (ja) | 2000-05-09 |
| EP0891552A1 (fr) | 1999-01-20 |
| ATE236407T1 (de) | 2003-04-15 |
| BR9708421A (pt) | 1999-08-03 |
| US20050048582A1 (en) | 2005-03-03 |
| DE69720433D1 (de) | 2003-05-08 |
| WO1997037227A1 (fr) | 1997-10-09 |
| EP0891552B2 (fr) | 2008-12-31 |
| AU2180897A (en) | 1997-10-22 |
| DE69720433T2 (de) | 2004-03-11 |
| CA2250800C (fr) | 2004-02-17 |
| US6972177B1 (en) | 2005-12-06 |
| AR006494A1 (es) | 1999-08-25 |
| DE69720433T3 (de) | 2009-07-30 |
| JP3333213B2 (ja) | 2002-10-15 |
| EP0891552B1 (fr) | 2003-04-02 |
| NO984602L (no) | 1998-12-03 |
| NO984602D0 (no) | 1998-10-01 |
| DK0891552T4 (da) | 2009-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210011028A1 (en) | Biomarker detection process and assay of neurological condition | |
| NO321571B1 (no) | Fremgangsmate for immunologisk pavisning av prionsykdom, diagnostisk testsett til slik pavisning, samt anvendelse av testsettet. | |
| Hardt et al. | A comparative study of immunohistochemical methods for detecting abnormal prion protein with monoclonal and polyclonal antibodies | |
| ES2230551T3 (es) | Procedimientos para ayudar al diagnostico de la enfermedad de alzheimer mediante la medicion del peptido (x- 41)amiloide beta y de la proteina tau. | |
| ES2264691T3 (es) | Diagnostico precoz de enfermedades conformacionales. | |
| US7566543B2 (en) | Prion test | |
| US20020137112A1 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| US20100136573A1 (en) | Diagnosing neurodegenerative diseases | |
| CZ295412B6 (cs) | Monoklonální protilátka a koktejl protilátek, které se specificky vážou ke konzervovanému epitopu prionových proteinů, buněčné linie produkující tyto protilátky a způsob detekce PrP-Sc proteinu | |
| JP2007319127A (ja) | アルツハイマー病の診断方法 | |
| Christie et al. | Differential regulation of inhibitors of apoptosis proteins in Alzheimer’s disease brains | |
| KR20110049781A (ko) | 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제 | |
| Silva et al. | Determining the relative susceptibility of four prion protein genotypes to atypical scrapie | |
| NZ525616A (en) | A urine test for the diagnosis of prion diseases | |
| JP2005292108A (ja) | インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット | |
| AU764960B2 (en) | Diagnosis of demyelinating or spongiform disease | |
| US20140271463A1 (en) | Bri2 as a novel biomarker for alzheimer's disease | |
| Koo et al. | Immunohistochemical detection of prion protein (PrP-Sc) and epidemiological study of BSE in Korea | |
| Raine et al. | Evaluating the inter-species transmission risk of amyloid beta peptide aggregates via ingestion | |
| Wu et al. | Spontaneous prion disease in homozygous and heterozygous transgenic mouse models of T188K genetic Creutzfeldt-Jakob disease | |
| Raine et al. | Evaluating the transmission risk of amyloid beta peptide via ingestion | |
| US20130217045A1 (en) | Use of Functional Autoantibodies in Alzheimer Disease | |
| JP2021060289A (ja) | 細胞内コレステロールレベルに関連する疾患の、診断用マーカー、診断を補助する方法、診断のためにデータを収集する方法、罹患可能性を評価する方法、及び診断用キット | |
| Taema | The in vitro characterisation of prion diseases of sheep | |
| Akatsu et al. | sereres de eer-BERC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |